Return of Hunan Business Investment of 220 Million Yuan: Veliter Oligonucleotide Project Settles in Wangcheng Economic Development Zone, with an Annual Production Expected to Reach 3 Billion Yuan.

Returning to Xiangshan Investment of 220 million yuan, with an annual output reaching 3 billion yuan, Veliter Oligonucleotide Project settles in Wangcheng Economic Development Zone.

On August 31st, Wangcheng Economic Development Zone’s pharmaceutical and medical industry chain received good news as Shenzhen Veliter Biomedical Technology Co., Ltd. (Veliter) announced the settlement of its oligonucleotide project in the Wangcheng Economic Development Zone. The project plans to invest 220 million yuan in constructing a mol-scale oligonucleotide production project with a planned annual capacity of approximately 120 kilograms.

As a type of short-chain nucleic acid, oligonucleotides are composed of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). By precisely “silencing” certain genes through the principle of complementary base pairing with DNA, mRNA, or pre-mRNA, they can prevent the expression of many proteins. In short, oligonucleotides can successfully inhibit the onset or treatment of diseases at the genetic level.

Currently, Veliter possesses a complete platform for the quality analysis development/validation of therapeutic oligonucleotides, as well as medium-scale non-GMP and GMP production manufacturing. The company mainly produces oligonucleotide intermediates, with a planned annual capacity of 15-20 kilograms and an estimated order volume of about 12 million yuan in 2022.

“Today is a crucial step for us. By establishing this important base in the development zone, we will continue to strive towards becoming a leader in the domestic and global industry,” said Xu Rongsong, Chairman of Veliter, at the signing ceremony. He expressed confidence in the project’s establishment and settlement, having felt the entrepreneurial atmosphere and hardworking spirit of the Wangcheng Economic Development Zone during negotiations. The company will accelerate its pace of innovation, continuously achieve technological breakthroughs, and grow rapidly, providing reliable support for the advancement of the medical industry.

Zhou Kai, Secretary of the Party Working Committee of Wangcheng Economic Development Zone, stated that the settlement of the project will drive the rapid development of the pharmaceutical and medical device industry in the zone. Currently, the zone is vigorously introducing leading enterprises and developing key characteristic industries, focusing on promoting the integration of industry and city, and achieving significant economic and social development. It is hoped that companies can lead the development momentum of characteristic industries and promote the rapid development of domestic and international industries. The zone will adhere to the “Four Prompts” service standard, striving to provide comprehensive resource element guarantees for enterprises and help projects settle in quickly.

It is reported that the high-quality factory buildings, extensive carrying space, and scientific industrial area planning provided by Changsha Medical Device Industrial Park, Wangda Zhizao Town Creative Island, and others, as well as the professional service advantages of Haicrow Bio and Baoyumingzhi in handling registration certificates for second and third-class products and industrialization of engineering-to-production, have attracted high-quality projects at home and abroad to settle in Wangcheng Economic Development Zone. As of July this year, there are over 60 companies in the zone’s pharmaceutical and medical device industry chain, achieving new breakthroughs in industrial development.